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Introduction {#sec005}
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease with the prevalence of 0.2--1% among adult population in Europe and North-America \[[@pone.0119683.ref001]\]. RA affects physical health causing pain, stiffness, progressive joint destruction and physical disability. Medical treatment, joint replacement surgery and productivity losses due to sick leave and early retirements lead to significant expenses for society \[[@pone.0119683.ref002]\]. The treatment target of RA is remission or low disease activity and the medication initially comprises conventional disease-modifying antirheumatic drugs (cDMARDs) such as methotrexate (MTX), sulphasalazine (SSZ), hydroxychloroquine (HCQ) and leflunomide (LEF), low-dose prednisolone and their combinations \[[@pone.0119683.ref003]\]. However, not all patients achieve remission or low disease activity with cDMARDs due to intolerance or lack of effectiveness. Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd.)). Biologics have proven to be an effective treatment for RA, but because of the high price, they are recommended only for patients with insufficient response or intolerance to cDMARDs \[[@pone.0119683.ref003]--[@pone.0119683.ref006]\].

Economic evaluations provide information on the benefits and costs of these expensive treatments to aid the optimal utilization of limited healthcare resources \[[@pone.0119683.ref007]\]. Cost-effectiveness analysis (CEA) is the most typical form of economic evaluation for health care interventions. In CEA, costs and effectiveness of two or more treatments are compared. The costs are measured in monetary units and effectiveness in natural units, for example in life years or pain free days. Cost-utility analysis (CUA) is a subtype of CEA, applying quality adjusted life years (QALY) as a measure of effectiveness. The primary outcome measure in CUAs is incremental cost-effectiveness ratio ICER, which describes the ratio of the additional costs of a treatment (compared to an alternative) to QALYs gained. An ICER is not reported if one treatment is both cheaper and more effective than another, e.g. if it is dominant.

Biologics for RA are an important target for economic evaluations because of the associated high costs. Previous systematic reviews suggest that biologics might be cost-effective at the willingness to pay (WTP) threshold of 50,000--100,000 \$/QALY among patients with insufficient treatment response to cDMARD but not in cDMARD naïve patients \[[@pone.0119683.ref008]--[@pone.0119683.ref010]\]. However, these reviews involve some weaknesses such as lack of quality assessment \[[@pone.0119683.ref009]\], insufficient reporting of study characteristics \[[@pone.0119683.ref008]\] or omission of between-biologics comparison \[[@pone.0119683.ref010]\]. The aim of our systematic review is to identify all existing studies examining the cost-utility of one or more biologics for RA in adults, assess their quality and report their results systematically.

Methods {#sec006}
=======

Literature search {#sec007}
-----------------

We performed a literature search aiming to identify existing CUAs assessing the cost-effectiveness of biologics for treatment of RA. The search covering Medline, SCOPUS (including EMBase), Cochrane library (Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, Cochrane Database of Systematic Reviews, NHS Economic Evaluation Database, Cochrane Central Register of Controlled Trials and Cochrane Methodology Register), ACP Journal club and Web of science was executed in March 2013 using a search strategy developed with a librarian. The search strategy included terms describing study design (CUA), intervention (Biologics) and patients (RA) in different spellings. The complete search strategy for PubMed is presented in [S1 File](#pone.0119683.s002){ref-type="supplementary-material"}.

No time or language restrictions were made to the literature search. The number of non-English publications was used to investigate the existence of a language bias and publication bias was assessed based on the number of conference abstract published as full-text.

Study selection {#sec008}
---------------

All references identified by the literature search were imported to reference management software (Refworks), where duplicate records were removed. Of the remaining references, the CUAs of one or more currently available biologics for the treatment of RA in adults were selected using a pre-defined inclusion and exclusion criteria ([S1 Table](#pone.0119683.s004){ref-type="supplementary-material"}). The evaluation for inclusion was conducted independently by two persons (JJ and KA) at first by titles and afterwards by full-text. In case of disagreement, a third opinion (MB) was requested. Studies without active comparison treatment (cDMARDs or other biologics) or QALYs as measure of effectiveness were excluded from this systematic review. Reporting of ICER was required, if applicable. Studies published only as conference abstracts and articles without English full-text were excluded.

Data collection {#sec009}
---------------

The Data on patients, interventions, controls, study design (country, perspective, time horizon, the year of resource utilization, included costs, discount rate, the source of effectiveness, the instrument for utility measures, study funding) and outcomes were extracted using a Microsoft Excel---based collection form. Two assessors (JJ and SH) independently extracted the data and discrepancies were resolved by consulting the third investigator (MB). Due to limited time and resources, authors were not contacted for complementary information.

Quality assessment {#sec010}
------------------

As currently recommended, the quality of economic evaluations included was assessed using the British Medical Journal (BMJ) checklist and in addition, the Philips\`checklist for modelling studies \[[@pone.0119683.ref011]--[@pone.0119683.ref013]\]. Two investigators (JJ and SH) assessed the quality of the studies independently and the third investigator (MB) was consulted when necessary. BMJ checklist involves 35 items and Philips' checklist 57 items. Quality scores based on fulfilment of items and average percentages of the applicable criteria met were calculated. To assess the relative quality of the studies we divided studies in three categories (good, adequate and poor quality) ranking them by using the average percentages.

Representation of results {#sec011}
-------------------------

The quantitative synthesis of the results of the studies included is not possible owing to heterogeneous study designs. Results of the CUAs included were stratified into five subgroups by type of drug used, previous treatments and response to them, and the comparator treatment as follows: 1) Biologics for cDMARDs naive patients, 2) Biologics compared with cDMARD in patients with an inadequate response to one or several cDMARDs, 3) Biologics compared with other biologics among patients with an inadequate response to cDMARDs, 4) Biologics compared with cDMARDs among patients with an inadequate response to TNFi(s) and 5) Biologics compared with other biologics among patients with an inadequate response to TNFi(s). Further, CUAs were stratified according to adequateness of the comparator treatment. Adequate comparator was defined as a cDMARD not used before \[[@pone.0119683.ref003]\].

To enable a comparison of the results, all of the reported costs were converted to euro using the European Central Bank exchange rates (<http://sdw.ecb.europa.eu>) and adjusted to the price level of the year 2013 using the price index of Health care expenditure in Finland (Statistics Finland). ICERs including only direct costs were considered primary results due to differences in the ways indirect costs (e.g. productivity losses) were calculated in studies. In addition, ICERs including both direct and indirect costs were presented as secondary outcomes, if reported in the original studies.

Results {#sec012}
=======

Altogether, 4653 non-duplicate references were identified with the literature search, of which 3113 were excluded during title and abstract screening ([Fig. 1](#pone.0119683.g001){ref-type="fig"}). After the assessment of 237 full-text articles, 41 were included in the current review. A majority of the studies excluded by full-text assessment did not meet the inclusion criteria (105 studies) or were published only as conference abstracts (71 studies). The list of the articles excluded after full-text assessment is displayed in [S2 File](#pone.0119683.s003){ref-type="supplementary-material"}.

![Flow chart of the study selection process.](pone.0119683.g001){#pone.0119683.g001}

Characteristics of studies included in the current review {#sec013}
---------------------------------------------------------

The 41 CUAs included were published 2002--2013 \[[@pone.0119683.ref014]--[@pone.0119683.ref054]\]. One study was based on empiric cost and effectiveness data from a randomised controlled trial (RCT) \[[@pone.0119683.ref019]\], two on observational data \[[@pone.0119683.ref016],[@pone.0119683.ref037]\] while the remaining 38 studies used a modelling approach with multiple data sources \[[@pone.0119683.ref014],[@pone.0119683.ref015],[@pone.0119683.ref017],[@pone.0119683.ref018],[@pone.0119683.ref020]--[@pone.0119683.ref036],[@pone.0119683.ref038]--[@pone.0119683.ref054]\]. In 33 of the 38 modelling studies effectiveness estimates were derived from one or more RCTs, while five modelling studies applied effectiveness obtained from national registers. A summary of the characteristics of the CUAs included is shown in [Table 1](#pone.0119683.t001){ref-type="table"}.

10.1371/journal.pone.0119683.t001

###### Characteristics of the studies included in the current review.

![](pone.0119683.t001){#pone.0119683.t001g}

  Study, Year of publication, Country                                    Patients                                                                                             Biologic treatment(s)                                                                                                                                                                                                                                                Comparator                                                                                                                                        Perspective                              Time horizon                                               Study type                                  Source of effectiveness                                         Instrument for utility measures                                                 Discount rate[\*](#t001fn002){ref-type="table-fn"}
  ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------- ------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------
  Bansback et al. 2005, Sweden \[[@pone.0119683.ref041]\]                Moderate to severe RA, inadequate response to 2 cDMARDs                                              ADA+MTX or ADA or ETN+MTX or ETN or IFX+MTX                                                                                                                                                                                                                          cDMARD                                                                                                                                            Policy maker                             Lifetime                                                   Patient-level transition state model        RCTs                                                            HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                3%
  Barbieri et al. 2005, UK \[[@pone.0119683.ref051]\]                    Severe RA, inadequate response to MTX                                                                IFX+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Payer (UK NHS)                           Lifetime (model), 1 and 2 years and lifetime (treatment)   Markov model                                RCT                                                             VAS                                                                             Costs 6%, benefits 1.5%
  Barton et al. 2004, UK \[[@pone.0119683.ref050]\]                      RA, inadequate response to SSZ or MTX                                                                ETN / IFX➔ cDMARDs                                                                                                                                                                                                                                                   cDMARDs: GST ➔ AZA ➔ D-PEN ➔HCQ➔ LEF ➔ CSA ➔ MTX/CSA➔ Palliation                                                                                  Payer (UK NHS)                           Lifetime                                                   Individual sampling model                   RCTs                                                            EQ-5D converted from HAQ, QoL = 0.862--0.327 x HAQ                              Costs 6%, benefits 1.5%
  Brennan et al. 2004, UK \[[@pone.0119683.ref049]\]                     RA, inadequate response to at least 2 cDMARDs (MTX, SSZ)                                             ETN➔ cDMARDs                                                                                                                                                                                                                                                         cDMARDs: GST➔LEF➔CSA                                                                                                                              Payer                                    Lifetime                                                   Individual patient-level simulation model   RCT                                                             EQ-5D converted from HAQ, QoL = 0.86--0.20 x HAQ                                Costs 6%, benefits 1.5%
  Brennan et al. 2007, UK \[[@pone.0119683.ref015]\]                     RA, inadequate response to at least 2 cDMARDs                                                        TNFi (ETN, IFX, ADA)                                                                                                                                                                                                                                                 cDMARDs                                                                                                                                           Payer (UK NHS)                           Lifetime                                                   Individual sampling model                   British Registry (BSRBR)                                        EQ-5D converted from HAQ                                                        Costs 6%, benefits 1.5%
  Brodszky et al. 2010, Hungary \[[@pone.0119683.ref034]\]               Moderate to severe RA, inadequate response to cDMARDs and at least1 TNFi                             RTX                                                                                                                                                                                                                                                                  1.) MTX, 2.) Another TNFi                                                                                                                         Health care provider                     Lifetime (model), 2 infusions and 3 years (treatment)      Markov model                                RCTs                                                            EQ-5D converted from HAQ                                                        5%
  CADTH 2010, Canada \[[@pone.0119683.ref048]\]                          RA, inadequate response to at least 2 cDMARDs                                                        ADA or ETN or IFX or GOL or ABT or Optimal sequence of biologics                                                                                                                                                                                                     MTX                                                                                                                                               Health care provider                     5 years                                                    Markov model                                MTC                                                             HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                Not stated
  Chen et al. 2006, UK \[[@pone.0119683.ref028]\]                        1.) Early RA, no previous cDMARDs and 2.) RA, inadequate response to at least 2 cDMARDs (SSZ, MTX)   IFX+MTX / ADA+MTX / ETN+MTX / ETN / ADA➔cDMARDs or cDMARDs➔ IFX+MTX / ETN+MTX / ADA+MTX / ETN /ADA                                                                                                                                                                   cDMARDs:(MTX)➔ MTX+SSZ ➔ MTX+SSZ+HCQ ➔ LEF ➔ GST ➔ AZA (CSA ➔ CSA+MTX ➔ D-PEN or cDMARDs: MTX+SSZ+HCQ ➔ LEF ➔ GST ➔ AZA ➔ CSA ➔ CSA+MTX ➔ D-PEN   Payer (UK NHS)                           Lifetime                                                   Individual sampling model                   Meta-analysis in same report                                    EQ-5D converted from HAQ, QoL = 0.862--0.327 x HAQ                              Costs 6%, benefits 1.5%
  Chiou et al. 2004 \[[@pone.0119683.ref047]\]                           Moderate to severe RA                                                                                ETN+MTX or ETN or ADA+MTX or ADA or ANA+MTX or ANA or IFX+MTX                                                                                                                                                                                                        Comparison of biologics                                                                                                                           Payer                                    1 year                                                     Decision analytic model                     RCTs                                                            VAS converted from ACR20, ACR50, ACR70 and no ACR responses                     \-
  Clark et al. 2004, UK \[[@pone.0119683.ref022]\]                       RA, inadequate response to cDMARDs and TNFi (SSZ, MTX, HCQ, (GST), LEF, ETN, IFX)                    ANA➔cDMARDs or cDMARDs➔ANA                                                                                                                                                                                                                                           cDMARDs: (GST)➔ AZA➔CSA➔ MTX+CSA                                                                                                                  Payer (UK NHS)                           Lifetime                                                   Individual sampling model                   Meta-analysis in same report                                    EQ-5D converted from HAQ, QoL = 0.862--0.327 x HAQ                              Costs 6%, benefits 1.5%
  Coyle et al. 2006, Canada \[[@pone.0119683.ref046]\]                   RA, no response to cDMARDs (MTX, MTX+SSZ, MTX+SSZ+HCQ)                                               IFX+MTX / ETN➔GST or GST➔IFX+MTX / ETN                                                                                                                                                                                                                               GST                                                                                                                                               Third party payer (Ministry of Health)   5 years                                                    Markov model                                Systematic review in same report                                EQ-5D converted from HAQ                                                        5%
  Davies et al. 2009, USA \[[@pone.0119683.ref021]\]                     Early RA (\< 3 years), no previous MTX                                                               ADA+MTX / ETN / IFX+MTX ➔ cDMARDs or ADA+MTX➔ ETN➔ cDMARDs                                                                                                                                                                                                           cDMARDs: MTX ➔ MTX+HCQ ➔ LEF ➔ GST ➔ Palliation                                                                                                   Payer                                    Lifetime                                                   Individual patient-level simulation model   Several RCTs                                                    HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ                                3%
  Diamantopoulos et al. 2012, Italy \[[@pone.0119683.ref033]\]           RA, inadequate response to cDMARDs                                                                   TOC+MTX ➔ biologics: (ADA+MTX ➔ RTX+MTX ➔ ABA+MTX ➔ Palliation)                                                                                                                                                                                                      ETN+MTX ➔ biologics                                                                                                                               Payer                                    Lifetime                                                   Individual patient-level simulation model   MTC                                                             EQ-5D converted from HAQ, QoL = 0.82--0.11 x HAQ---0.07 x HAQ²                  3%
  Farahani et al. 2006, Canada \[[@pone.0119683.ref037]\]                RA                                                                                                   ETN + cDMARD                                                                                                                                                                                                                                                         cDMARD (MTX, SSZ, HCQ etc.)                                                                                                                       Societal                                 1 year                                                     Observational analysis, no modelling used   RCT and observational study (efficacy vs. effectiveness data)   EQ-5D converted from HAQ, QoL = 0.862--0.327 x HAQ                              \-
  Finckh et al. 2009, USA \[[@pone.0119683.ref027]\]                     Early RA (\< 3 months), no previous cDMARDs                                                          1.) cDMARDs ➔ 1.TNFi+MTX ➔ 2.TNFi+MTX➔ 3.TNFi 2.)1.TNFi+MTX ➔ 2.TNFi+MTX➔ 3.TNFi ➔ cDMARDs 3.)NSAID ➔ cDMARDs ➔ 1.TNFi+MTX ➔ 2.TNFi+MTX ➔ 3.TNFi                                                                                                                     Comparison of treatment 3 strategies containing TNFi                                                                                              Health care provider, societal           Lifetime                                                   Individual sampling model                   Meta-analysis                                                   EQ-5D converted from HAQ                                                        3%
  Hallinen et al. 2010, Finland \[[@pone.0119683.ref054]\]               Severe RA, no response to TNFi                                                                       RTX+MTX / ADA+MTX / ETN+MTX / IFX+MTX/ ABT+MTX➔ cDMARDs or Optimal sequence of biologics                                                                                                                                                                             cDMARDs: GST ➔ CSA+MTX                                                                                                                            Societal                                 Lifetime (up to the age of 100 years)                      Patient-level Markov model                  RCTs                                                            HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                3%
  Jobanputra et al. 2002, UK \[[@pone.0119683.ref032]\]                  RA, no response at least 2 cDMARDs (SSZ, MTX)                                                        ETN / IFX+MTX ➔ cDMARDs or cDMARDs➔ ETN / IFX+MTX                                                                                                                                                                                                                    cDMARDs: GST ➔ AZA ➔ D-PEN ➔ HCQ ➔ LEF ➔ CSA ➔ CSA+MTX                                                                                            Payer (UK NHS)                           Lifetime                                                   Individual sampling model                   Meta-analysis in same report                                    EQ-5D converted from HAQ                                                        Costs 6%, benefits 1.5%
  Kielhorn et al. 2008, UK \[[@pone.0119683.ref031]\]                    RA, inadequate response to 2 cDMARDs and a TNFi                                                      RTX ➔ MTX ➔ cDMARDs or RTX+MTX ➔ ADA+MTX ➔ IFX+MTX ➔ cDMARDs                                                                                                                                                                                                         cDMARDs: LEF ➔ GST ➔ CSA ➔ MTX or ADA+MTX ➔ IFX+MTX ➔ cDMARDs                                                                                     Payer (UK NHS)                           Lifetime                                                   Patient-level Markov model                  RCTs                                                            HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                3,5%
  Kobelt et al. 2003, UK & Sweden \[[@pone.0119683.ref052]\]             Advanced RA, no response to MTX                                                                      IFX+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Not stated                               10 years (model), 1 and 2 years (treatment)                Markov model                                RCT                                                             EQ-5D converted from HAQ                                                        UK: Costs 6%, benefits 1.5%; Sweden: 3%
  Kobelt et al. 2004, Sweden \[[@pone.0119683.ref016]\]                  RA, inadequate response to at least 2 cDMARDs, including MTX                                         TNF (IFX, ETN)                                                                                                                                                                                                                                                       Baseline (DMARD)                                                                                                                                  Societal                                 1 year                                                     Observational analysis, no modelling used   Observational study                                             EQ-5D                                                                           \-
  Kobelt et al. 2005, Sweden \[[@pone.0119683.ref036]\]                  RA, inadequate response to cDMARD (excluding MTX)                                                    ETN+MTX or ETN                                                                                                                                                                                                                                                       MTX                                                                                                                                               Societal                                 5 and 10 years (model); 2, 5 and 10 years (treatment)      Patient-level Markov model                  RCT                                                             EQ-5D converted from HAQ                                                        3%
  Kobelt et al. 2011, Sweden \[[@pone.0119683.ref038]\]                  Early RA, no previous MTX                                                                            ETN+MTX ➔ Half-dose ETN+MTX ➔ cDMARD / 2. biologic                                                                                                                                                                                                                   MTX ➔ cDMARD / biologic                                                                                                                           Societal                                 10 years                                                   Patient-level Markov model                  RCT                                                             EQ-5D converted from HAQ                                                        3%
  Lekander et al. 2010, Sweden \[[@pone.0119683.ref026]\]                RA, inadequate response to at least 2 cDMARDs                                                        IFX + cDMARD                                                                                                                                                                                                                                                         cDMARD                                                                                                                                            Societal                                 20 years                                                   Markov cohort model                         Registry (STURE)                                                EQ-5D converted from HAQ                                                        3%
  Lekander et al. 2013, Sweden \[[@pone.0119683.ref025]\]                1.) RA, inadequate response to at least 2 cDMARDs or 2.) RA, inadequate response to a TNFi           TNFi (ADA, IFX, ETN) + cDMARD or TNFi or ETN+cDMARD or ETN                                                                                                                                                                                                           cDMARD                                                                                                                                            Societal                                 20 years                                                   Markov cohort model                         Registry (Swedish Rheumatology Register)                        EQ-5D converted from HAQ                                                        3%
  Lindgren et al. 2009, Sweden \[[@pone.0119683.ref045]\]                RA, inadequate response to a TNFi                                                                    RTX ➔ 2.TNFi (ADA, ETN, IFX)                                                                                                                                                                                                                                         2\. TNFi ➔ 3. TNFi                                                                                                                                Societal                                 Lifetime                                                   Discrete event simulation model             RCT and Registry (SSTAG)                                        EQ-5D converted from HAQ and DAS 28                                             3%
  Malottki et al. 2011, UK \[[@pone.0119683.ref053]\]                    RA, inadequate response to a TNFi                                                                    ADA / ETN / IFX / RTX / ABT ➔ cDMARDs                                                                                                                                                                                                                                cDMARDs: LEF ➔ GST ➔ CSA ➔ AZA                                                                                                                    Payer (UK HNS)                           Lifetime                                                   Individual sampling model                   Meta-analysis                                                   EQ-5D converted from HAQ, QoL = 0.804--0.203 x HAQ---0.045 x HAQ²               3,5%
  Marra et al. 2007, Canada \[[@pone.0119683.ref044]\]                   RA, refractory to standard therapy                                                                   IFX+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Societal                                 10 years                                                   Patient-level Markov model                  RCT                                                             HUI-2, HUI-3, EQ-5D and SF6D converted from HAQ                                 3%
  Merkesdal et al. 2010, Germany \[[@pone.0119683.ref018]\]              RA, inadequate response to ETN                                                                       RTX+MTX ➔ ADA+MTX ➔ IFX+MTX ➔ GST ➔ CSA ➔ MTX                                                                                                                                                                                                                        ADA+MTX ➔ IFX+MTX ➔ GST ➔ CSA ➔ MTX                                                                                                               Payer                                    Lifetime                                                   Patient-level Markov model                  RCTs                                                            HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                3,5%
  Nguyen et al. 2012, USA \[[@pone.0119683.ref024]\]                     Moderate to severe RA, moderate or no response to MTX                                                ADA+MTX / IFX+MTX / CER+MTX / GOL+MTX ➔ TOC                                                                                                                                                                                                                          ETN+MTX ➔ TOC / MTX ➔ TOC                                                                                                                         Payer                                    5 years                                                    Markov cohort model                         RCTs (Systematic review)                                        VAS converted from ACR20, ACR50, ACR70 and no ACR responses                     3%
  Schipper et al. 2011, the Netherland \[[@pone.0119683.ref030]\]        Early RA, no previous cDMARDs                                                                        1.)1.TNFi+MTX ➔ 2.TNFi+MTX➔ RTX+MTX 2.)MTX+LEF➔ 1.TNFi+MTX ➔ 2.TNFi+MTX➔ RTX+MTX 3.)MTX(MTX+LEF ➔ 1.TNFi+MTX ➔ 2.TNFi+MTX➔ RTX+MTX                                                                                                                                   Comparison of treatment 3 strategies containing TNFi                                                                                              Payer, societal                          5 years                                                    Patient-level Markov model                  Registries (Nijmegen and DREAM)                                 EQ-5D                                                                           4%
  Soini et al. 2012, Finland \[[@pone.0119683.ref020]\]                  Moderate to severe RA, inadequate response to at least 1 cDMARD                                      TOC+MTX / ADA+MTX / ETN+MTX ➔ RTX+MTX ➔ IFX+MTX ➔ LEF ➔ CSA ➔ MTX                                                                                                                                                                                                    MTX➔ RTX+MTX ➔ IFX+MTX ➔ LEF ➔ CSA ➔ MTX                                                                                                          Payer, societal                          Lifetime                                                   Individual sampling model                   MTC                                                             EQ-5D converted from HAQ, QoL = 0.82--0.11 x HAQ---0.07 x HAQ²                  3%
  Spalding & Hay 2006, USA \[[@pone.0119683.ref014]\]                    Early RA (\< 3 months), no previous cDMARDs                                                          ADA+MTX or ADA or IFX+MTX or ETN                                                                                                                                                                                                                                     MTX                                                                                                                                               Payer, societal                          Lifetime                                                   Markov model                                Several RCTs                                                    HUI3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE + 0,001 x AGE   3%
  Tanno et al. 2006, Japan \[[@pone.0119683.ref035]\]                    RA, inadequate response to busillamine (cDMARD)                                                      ETN ➔ cDMARDs                                                                                                                                                                                                                                                        cDMARDs: MTX ➔ SSZ ➔ MTX+SSZ ➔ no cDMARD                                                                                                          Societal                                 Lifetime                                                   Markov model                                RCT                                                             EQ-5D converted from HAQ, QoL = 0.74--0.17 x HAQ                                Costs 6%, benefits 1.5%
  Wailoo et al. 2008, USA \[[@pone.0119683.ref040]\]                     Established RA                                                                                       ADA / IFX / ETN / ANA ➔ cDMARD                                                                                                                                                                                                                                       Comparison of biologics                                                                                                                           Payer (Medicare)                         Lifetime                                                   Model, unspecified                          Meta-analysis                                                   EQ-5D converted from HAQ                                                        3%
  van den Hout et al. 2009, the Netherlands \[[@pone.0119683.ref019]\]   Early RA (≤ 2 years), no previous cDMARDs                                                            1.)MTX ➔ MTX+SSZ ➔ MTX+SSZ+HCQ➔ MTX+SSZ+HCQ+CS ➔ IFX+MTX ➔ MTX+CSA+CS ➔ LEF ➔ AZA+CS 2.)IFX+MTX➔ SSZ ➔ LEF ➔MTX+CSA+ CS ➔ GST+CS ➔ AZA+CS 3.)MTX(SSZ➔ LEF ➔ IFX+MTX ➔ GST+ CS ➔ MTX+CSA+CS ➔ AZA+ CS 4.)MTX+SSZ+CS➔ MTX+CSA+ CS ➔ IFX+MTX ➔ LEF ➔ GST+ CS ➔ AZA+CS   Comparison of treatment 4 strategies containing TNFi                                                                                              Societal                                 2 years                                                    Empiric CUA, no modelling used10            RCT                                                             EQ-5D (British and Dutch valuations), SF6D, TTO                                 3%
  Welsing et al. 2004, the Netherland \[[@pone.0119683.ref023]\]         Active RA, inadequate response to at least 2 cDMARDs (SSZ, MTX)                                      ETN➔Usual care or LEF➔ETN(Usual care or ETN➔LEF(Usual care                                                                                                                                                                                                           Usual care or LEF(Usual care                                                                                                                      Societal, Payer (Third party payer)      5 years                                                    Markov model                                RCTs                                                            EQ-5D converted from DAS28 responses                                            4%
  Vera-Llonch et al. 2008a, USA \[[@pone.0119683.ref017]\]               Moderate to severe RA, inadequate response to MTX                                                    ABT+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Third party payer                        10 years, lifetime                                         Patient-level simulation model              RCT                                                             EQ-5D converted from HAQ                                                        3%
  Vera-Llonch et al. 2008b, USA \[[@pone.0119683.ref043]\]               Moderate to severe RA, inadequate response to TNFi                                                   ABT+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Third party payer                        10 years, lifetime                                         Patient-level simulation model              RCT                                                             EQ-5D converted from HAQ                                                        3%
  Wong et al. 2002 \[[@pone.0119683.ref039]\]                            Active refractory RA                                                                                 IFX+MTX                                                                                                                                                                                                                                                              MTX                                                                                                                                               Payer, societal                          Lifetime (model), 54 weeks (treatment)                     Markov cohort model                         RCT                                                             VAS                                                                             3%
  Wu et al. 2012, China \[[@pone.0119683.ref029]\]                       Moderate to severe RA, inadequate response to at least 2 cDMARDs (including MTX)                     ETN / IFX / ADA➔ cDMARDs or ETN(RTX➔ cDMARDs or IFX(RTX➔ cDMARDs or ADA(RTX➔ cDMARDs                                                                                                                                                                                 cDMARDs: GST ➔ LEF ➔ CSA ➔ MTX                                                                                                                    Payer, societal                          Lifetime                                                   Markov cohort model                         RCTs                                                            HUI-3 converted from HAQ, QoL = 0.76--0.28 x HAQ + 0.05 x FEMALE                3%
  Yuan et al. 2010, USA \[[@pone.0119683.ref042]\]                       Active RA, inadequate response to a TNFi                                                             ABA+MTX / RTX+MTX ➔ MTX                                                                                                                                                                                                                                              MTX                                                                                                                                               Payer                                    Lifetime                                                   Patient-level simulation model              RCTs                                                            EQ-5D converted from HAQ                                                        3%

➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, ANA = anakinra, AZA = azathioprine, bDMARD = biologic disease-modifying antirheumatic drugs, CADTH = Canadian Agency for Drugs and Technologies in Health, cDMARD = conventional disease-modifying antirheumatic drugs, CER = certolizumab pegol, CS = corticosteroids, CSA = cyclosporin A, DAS28 = Disease Activity Score 28, D-PEN = D-Penicillin, EQ-5D = EuroQol-5D, ETN = etanercept, GOL = golimumab, GST = Gold, HAQ = Health Assessment Questionnaire, HCQ = hydroxychloroquine, HUI-2 = Health Utility Index 2, HUI-3 = Health utility Index 3, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, LEF = leflunomide, MTC = mixed-treatment comparison, MTX = methotrexate, NSAID = non-steroidal anti-inflammatory drug, QALY = quality-adjusted life year, QoL = quality of life, RA = rheumatoid arthritis, RCT = randomized controlled trial, RTX = rituximab, SF-6D = Short Form 6D, SSZ = sulfasalazine, TNFi = TNF inhibitor, TOC = tocilizumab, TTO = Time Trade-off, UK NHS = The National Health Service of the United Kingdom, VAS = the Visual Analogue Scale,

\*People and society tend to value present costs and benefits more than future ones. This is taken into account by discounting future costs and benefits with a predefined rate.

Cost-effectiveness of biologics in patients with early RA and naïve to cDMARDs {#sec014}
------------------------------------------------------------------------------

The cost-effectiveness of biologics for patients with early RA and naïve to cDMARDs were analysed in seven studies ([Table 2](#pone.0119683.t002){ref-type="table"}). Four studies performed a comparison between biologics and cDMARDs \[[@pone.0119683.ref014],[@pone.0119683.ref021],[@pone.0119683.ref028],[@pone.0119683.ref038]\]. The ICERs of TNFi in comparison to cDMARDs ranged from 39,000 to 1 273,000 €/QALY when only direct costs were considered ([Table 2](#pone.0119683.t002){ref-type="table"}). IFX was associated with the highest ICERs ranging from 422,000 to 1 273,000 €/QALY while ICERs for ETN and ADA as a monotherapy were below 100,000 €/QALY. As a combination therapy with MTX, ICERs for ETN and ADA were substantially higher. If both direct and indirect costs were considered, ICERs for biologics were slightly more favourable.

10.1371/journal.pone.0119683.t002

###### Cost-effectiveness of biologics in cDMARD naïve patients.

![](pone.0119683.t002){#pone.0119683.t002g}

  Treatments                                                                                                                          Study                                                 ICER €/QALY (only direct costs)   ICER €/QALY (direct and indirect costs)   Results of deterministic sensitivity analysis €/QALY   Source of research funding
  ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- --------------------------------- ----------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------
  **TNFi vs. cDMARDs**                                                                                                                                                                                                                                                                                                         
  IFX                                                                                                                                 Chen et al. 2006 \[[@pone.0119683.ref028]\]           1 273,007                         \-                                        40,876---dominated                                     NICE (UK)
  Davies et al. 2009 \[[@pone.0119683.ref021]\]                                                                                       Extended dominance by ADA                             Extended dominance by ADA         \-                                        Abbott                                                 
  Spalding & Hay 2006 \[[@pone.0119683.ref014]\]                                                                                      422,215                                               \-                                422,114--573,650                          University of Southern California                      
  ADA                                                                                                                                 Chen et al. 2006 \[[@pone.0119683.ref028]\]           152,021 (ADA+MTX)                 \-                                        40,876---dominated (ADA+MTX)                           NICE (UK)
  Chen et al. 2006 \[[@pone.0119683.ref028]\]                                                                                         58,672 (ADA)                                          \-                                36,983---dominated (ADA)                  NICE (UK)                                              
  Davies et al. 2009 \[[@pone.0119683.ref021]\]                                                                                       41,178 (ADA+MTX)                                      20,413                            31,435--61,124                            Abbott                                                 
  Davies et al. 2009 \[[@pone.0119683.ref021]\]                                                                                       37,309 (ADA+MTX ➔ ETN)                                \-                                \-                                        Abbott                                                 
  Spalding & Hay 2006 \[[@pone.0119683.ref014]\]                                                                                      200,620 (ADA+MTX)                                     \-                                200,570 (ADA+MTX)                         University of Southern California                      
  Spalding & Hay 2006 \[[@pone.0119683.ref014]\]                                                                                      65,745 (ADA)                                          \-                                67,962 (ADA)                              University of Southern California                      
  ETN                                                                                                                                 Spalding & Hay 2006 \[[@pone.0119683.ref014]\]        92,503                            81,408                                    80,027--108,051                                        University of Southern California
  Davies et al. 2009 \[[@pone.0119683.ref021]\]                                                                                       Extended dominance by ADA                             Extended dominance by ADA         \-                                        Abbott                                                 
  Kobelt et al. 2011 \[[@pone.0119683.ref038]\]                                                                                       38,639                                                15,315                            2,473--38,639                             Wyeth (now Pfizer)                                     
  Chen et al. 2006 \[[@pone.0119683.ref028]\]                                                                                         332,850 (ETN+MTX)                                     \-                                35,037---dominated (ETN+MTX)              NICE (UK)                                              
  Chen et al. 2006 \[[@pone.0119683.ref028]\]                                                                                         96,157 (ETN)                                          \-                                35,037--231,633 (ETN)                     NICE (UK)                                              
  **Comparison of treatment strategies containing TNFi**                                                                                                                                                                                                                                                                       
  **1.)**MTX➔MTX+SSZ➔ MTX+SSZ+HCQ➔ MTX+SSZ+HCQ+CS ➔IFX(MTX+CSA+ CS ➔ LEF➔AZA+CS 2.)IFX(SSZ➔LEF➔ MTX+CSA+CS➔GST+CS➔AZA+CS              Van den Hout et al. 2009 \[[@pone.0119683.ref019]\]   2 vs.1: 215,256                   2 vs.1: 147,280                           24,924--362,537                                        Dutch Health Care Insurance Board, Schering-Plough and Centocor (now Janssen Biologics B.V)
  **1.)**1.TNFi➔2.TNFi➔RTX **2.)**MTX+LEF➔1.TNFi➔ 2.TNFi➔RTX **3.)**MTX➔MTX+LEF ➔1.TNFi ➔2.TNFi➔RTX                                   Schipper et al. 2011 \[[@pone.0119683.ref030]\]       2 vs.3: 462,576                   2 vs.3: 461,476                           2 vs.1: 456,946--791,788                               Wyeth (now Pfizer)
  Schipper et al. 2011 \[[@pone.0119683.ref030]\]                                                                                     1 vs.3: 145,784                                       1 vs.3: 143,831                   1 vs.3: 120,136--545,603                  Wyeth (now Pfizer)                                     
  Schipper et al. 2011 \[[@pone.0119683.ref030]\]                                                                                     2 vs.1: 1 dominates                                   2 vs.1: 1 dominates               \-                                        Wyeth (now Pfizer)                                     
  **1.)**cDMARDs ➔ 1.TNFi ➔ 2.TNFi ➔ 3.TNFi **2.**➔1.TNFi ➔ 2.TNFi ➔ 3.TNFi ➔ cDMARDs **3.)**NSAID ➔ cDMARDs➔ 1.TNFi ➔2.TNFi➔3.TNFi   Finckh et al. 2009 \[[@pone.0119683.ref027]\]         1 vs.3: 4,234                     1 vs.3: 1 is cost-saving                  1 vs.3: 1 is cost saving---14,738                      Arthritis research foundation and an anonymous donor
  Finckh et al. 2009 \[[@pone.0119683.ref027]\]                                                                                       2 vs.3: 635,597                                       2 vs.3: 471,575                   2 vs.3: 30,624--3 dominates               Arthritis research foundation and an anonymous donor   
  Finckh et al. 2009 \[[@pone.0119683.ref027]\]                                                                                       2 vs.1: 1 dominates                                   2 vs.1: 1 dominates               2 vs.1: 40,956--1 dominates.              Arthritis research foundation and an anonymous donor   

➔ = switch to next treatment in case of an inadequate response, ADA = adalimumab, AZA = azathioprine, cDMARD = conventional disease-modifying antirheumatic drugs, CS = corticosteroids, CSA = cyclosporin A, ETN = etanercept, GST = Gold, HCQ = hydroxychloroquine, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, LEF = leflunomide, MTX = methotrexate, NICE = National Institute for Health and Care Excellence, NSAID = non-steroidal anti-inflammatory drug, QALY = quality-adjusted life year, SSZ = sulfasalazine, TNFi = TNF inhibitor

Three out of the seven studies examined the cost-effectiveness of different treatment strategies for early RA including TNFi in all treatment options, with only its time of usage in a treatment sequence being altered \[[@pone.0119683.ref019],[@pone.0119683.ref027],[@pone.0119683.ref030]\]. Two studies found a late introduction of TNFi to be a dominant strategy compared to initiation of the treatment with TNFi. Meanwhile van den Hout and colleagues found the ICER for TNFi as a first-line treatment option to be 215,000 €/QALY compared to its later introduction ([Table 2](#pone.0119683.t002){ref-type="table"}).

Cost-effectiveness of biologics among patients with an inadequate response to cDMARD {#sec015}
------------------------------------------------------------------------------------

There were 21 studies comparing the biologics and cDMARDs in patients with an insufficient response to cDMARDs ([Table 3](#pone.0119683.t003){ref-type="table"}). When only direct costs were considered ICERs for IFX, ADA and ETN were 12,000--282,000; 44,000--274,000 and 40,000--708,000, respectively. ABT and TOC were associated with narrower ranges of ICERs (42,000 to 47,000 and 19,000 to 21,000, respectively). ICERs below 35,000 €/QALY were found in three studies \[[@pone.0119683.ref020],[@pone.0119683.ref029],[@pone.0119683.ref051]\] and below 50,000 €/QALY in ten studies \[[@pone.0119683.ref015],[@pone.0119683.ref017],[@pone.0119683.ref028],[@pone.0119683.ref039],[@pone.0119683.ref041],[@pone.0119683.ref049],[@pone.0119683.ref052]\]. The quality scores of the studies were not associated with the magnitude of ICER values. Adequate comparator was applied in nine of 21 CUAs \[[@pone.0119683.ref015],[@pone.0119683.ref023],[@pone.0119683.ref028],[@pone.0119683.ref029],[@pone.0119683.ref032],[@pone.0119683.ref035],[@pone.0119683.ref036],[@pone.0119683.ref046],[@pone.0119683.ref050]\]. These studies provided higher ICERs compared to other studies: only one CUAs with an adequate comparison treatment provided ICERs below 35,000 €/QALY for biologics when considering only direct costs \[[@pone.0119683.ref029]\].

10.1371/journal.pone.0119683.t003

###### Cost-effectiveness of biologics in comparison with cDMARD among patients with an insufficient response to cDMARD.

![](pone.0119683.t003){#pone.0119683.t003g}

  Biologic                                              Study                                                ICER €/QALY (only direct costs)                      ICER €/QALY (direct and indirect costs)   Results of deterministic sensitivity analysis €/QALY                                                                  Source of research funding
  ----------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  **IFX**                                               Bansback et al. 2005 \[[@pone.0119683.ref041]\]      69,717--93,665                                       \-                                        \-                                                                                                                    Abbott
  Barbieri et al. 2005 \[[@pone.0119683.ref051]\]       12,438--89,108                                       \-                                                   9,325--103,753                            Schering-Plough                                                                                                       
  Barton et al. 2004 \[[@pone.0119683.ref050]\]         166,921                                              \-                                                   96,287--213,008                           NICE (UK)                                                                                                             
  CADTH 2010 \[[@pone.0119683.ref048]\]                 Extended dominance by ADA                            \-                                                   \-                                        Health Canada and the governments of provinces and territories                                                        
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           59,173--270,563 (IFX➔cDMARDs)                        \-                                                   37,957---dominated (IFX➔cDMARDs)          NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           73,772 (cDMARDs➔IFX)                                 \-                                                   50,027--117,763 (cDMARDs➔IFX)             NICE (UK)                                                                                                             
  Coyle et al. 2006 \[[@pone.0119683.ref046]\]          98,132 (IFX➔GST)                                     \-                                                   85,279--138,948 (IFX➔GST)                 Health Canada and the governments of provinces and territories                                                        
  Coyle et al. 2006 \[[@pone.0119683.ref046]\]          84,931 (GST➔IFX)                                     \-                                                   71,298--101,084 (GST➔IFX)                 Health Canada and the governments of provinces and territories                                                        
  Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]     282,151 (IFX➔cDMARDs)                                \-                                                   128,590--641,955 (IFX➔cDMARDs)            NICE (UK)                                                                                                             
  Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]     230,698 (cDMARDs➔IFX)                                \-                                                   68,157--413,593 (cDMARDs➔IFX)             NICE (UK)                                                                                                             
  Kobelt et al. 2003 \[[@pone.0119683.ref052]\]         38,945--76,392                                       4,684--65,635                                        IFX is cost saving---60,597               Schering-Plough                                                                                                       
  Lekander et al. 2010 \[[@pone.0119683.ref026]\]       \-                                                   27,321                                               10,005--56,246                            Schering-Plough                                                                                                       
  Marra et al. 2007 \[[@pone.0119683.ref044]\]          \-                                                   30,267--66,008                                       IFX dominates---139,343                   Canadian Arthritis Network                                                                                            
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             20,254 (IFX)                                         20,150 (IFX)                                         \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             21,946 (IFX➔RTX)                                     21,833 (IFX➔RTX)                                     \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  Wong et al. 2002 \[[@pone.0119683.ref039]\]           44,737                                               13,348                                               IFX is cost saving---137,292              Schering-Plough and National Institutes of Health                                                                     
  **ADA**                                               Bansback et al. 2005 \[[@pone.0119683.ref041]\]      49,284--63,493 (ADA+MTX)                             \-                                        \-                                                                                                                    Abbott
  Bansback et al. 2005 \[[@pone.0119683.ref041]\]       59,949--94,478 (ADA)                                 \-                                                   \-                                        Abbott                                                                                                                
  CADTH 2010 \[[@pone.0119683.ref048]\]                 92,326                                               \-                                                   \-                                        Health Canada and the governments of provinces and territories                                                        
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           58,784--125,354 (ADA+MTX➔ cDMARDs)                   \-                                                   37,178--291,974 (ADA+MTX➔ cDMARDs)        NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           67,349--274,456 (ADA➔ cDMARDs)                       \-                                                   41,266- dominated (ADA➔ cDMARDs)          NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           57,811 (cDMARDs➔ ADA+MTX)                            \-                                                   43,018--83,699 (cDMARDs➔ ADA+MTX)         NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           78,054 (cDMARDs➔ADA)                                 \-                                                   52,750--124,770 (cDMARDs➔ADA)             NICE (UK)                                                                                                             
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             43,943 (ADA)                                         43,876 (ADA)                                         \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             38,689 (ADA➔ RTX)                                    38,641 (ADA➔ RTX)                                    \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  **ETN**                                               Bansback et al. 2005 \[[@pone.0119683.ref041]\]      51,581--74,972 (ETN+MTX)                             \-                                        \-                                                                                                                    Abbott
  Bansback et al. 2005 \[[@pone.0119683.ref041]\]       53,265--61,274 (ETN)                                 \-                                                   \-                                        Abbott                                                                                                                
  Barton et al. 2004 \[[@pone.0119683.ref050]\]         122,754                                              \-                                                   73,350--157,370                           NICE (UK)                                                                                                             
  Brennan et al. 2004 \[[@pone.0119683.ref049]\]        39,740                                               18,950                                               18 950--103 145                           Not stated, two of authors are employees of Wyeth (now Pfizer)                                                        
  CADTH 2010 \[[@pone.0119683.ref048]\]                 Dominated by ADA                                     \-                                                   \-                                        Health Canada and the governments of provinces and territories                                                        
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           55,475--96,935 (ETN+MTX➔ cDMARDs)                    \-                                                   34,648--187,058 (ETN+MTX➔ cDMARDs)        NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           59,173--92,264 (ETN➔cDMARDs)                         \-                                                   36,399--185,695 (ETN➔ cDMARDs)            NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           46,327 (cDMARDs➔ ETN+MTX)                            \-                                                   35,037--66,181 (cDMARDs➔ ETN+MTX)         NICE (UK)                                                                                                             
  Chen et al. 2006 \[[@pone.0119683.ref028]\]           46,132 (cDMARDs➔ ETN)                                \-                                                   35,232--65,013 (cDMARDs➔ ETN)             NICE (UK)                                                                                                             
  Coyle et al. 2006 \[[@pone.0119683.ref046]\]          125,661 (ETN➔ GST)                                   \-                                                   109,335--173,251 (ETN➔ GST)               Health Canada and the governments of provinces and territories                                                        
  Coyle et al. 2006 \[[@pone.0119683.ref046]\]          109,161 (GST➔ETN)                                    \-                                                   94 919--129,916 (GST(ETN)                 Health Canada and the governments of provinces and territories                                                        
  Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]     202,218 (ETN➔ cDMARDs)                               \-                                                   93,643--448,885 (ETN➔ cDMARDs)            NICE (UK)                                                                                                             
  Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]     174,388 (cDMARDs➔ ETN)                               \-                                                   51,662--312,186 (cDMARDs➔ ETN)            NICE (UK)                                                                                                             
  Kobelt et al. 2005 \[[@pone.0119683.ref036]\]         69,550 (ETN+MTX)                                     49,314--72,058 (ETN+MTX)                             33,704--69,550                            Wyeth (now Pfizer)                                                                                                    
  Kobelt et al. 2005 \[[@pone.0119683.ref036]\]         \-                                                   Dominated by ETN+MTX (ETN)                           \-                                        Wyeth (now Pfizer)                                                                                                    
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       \-                                                   52,671 (ETN+cDMARD)                                  33,922--78,770 (ETN+cDMARD)               Wyeth (now Pfizer)                                                                                                    
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       \-                                                   68,535 (ETN)                                         40,818--127,988 (ETN)                     Wyeth (now Pfizer)                                                                                                    
  Soini et al. 2012 \[[@pone.0119683.ref020]\]          22,745                                               \-                                                   9,437--57,025                             Roche                                                                                                                 
  Tanno et al. 2006 \[[@pone.0119683.ref035]\]          \-                                                   25,993                                               19,547--32,439                            Ministry of Education, Science, Sports and Culture and the Ministry of Health, Japan                                  
  Welsing et al. 2004 \[[@pone.0119683.ref023]\]        233,867 (LEF➔ ETN➔ Usual care vs. Usual care)        216,059 (LEF➔ ETN➔ Usual care vs. Usual care)        \-                                        Not stated                                                                                                            
  Welsing et al. 2004 \[[@pone.0119683.ref023]\]        413,169 (ETN➔ LEF➔ Usual care vs. Usual care)        392,539 (ETN➔ LEF➔Usual care vs. Usual care)         \-                                        Not stated                                                                                                            
  Welsing et al. 2004 \[[@pone.0119683.ref023]\]        440,322 (LEF➔ ETN(Usual care vs. LEF➔ Usual care)    419,588 (LEF➔ ETN➔ Usual care vs. LEF➔ Usual care)   \-                                        Not stated                                                                                                            
  Welsing et al. 2004 \[[@pone.0119683.ref023]\]        708,060 (ETN➔ LEF➔ Usual care vs. LEF➔ Usual care)   683,041 (ETN➔ LEF➔ Usual care vs. LEF➔ Usual care)   \-                                        Not stated                                                                                                            
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             58,711 (ETN)                                         58,684 (ETN)                                         \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  Wu et al. 2012 \[[@pone.0119683.ref029]\]             50,409 (ETN➔ RTX)                                    50,389 (ETN➔ RTX)                                    \-                                        Shanghai Hospital Association, National Natural Science Foundation of China and Shanghai Natural Science Foundation   
  **ABT**                                               CADTH 2010 \[[@pone.0119683.ref048]\]                Extended dominance by ADA                            \-                                        \-                                                                                                                    Health Canada and the governments of provinces and territories
  Vera-Llonch et al. 2008a \[[@pone.0119683.ref017]\]   42,382--47,177                                       \-                                                   36,976--69,134                            Bristol-Myers Squibb                                                                                                  
  **GOL**                                               CADTH 2010 \[[@pone.0119683.ref048]\]                Extended dominance by ADA                            \-                                        \-                                                                                                                    Health Canada and the governments of provinces and territories
  **TOC**                                               Soini et al. 2012 \[[@pone.0119683.ref020]\]         18,693--20,776                                       18,731--20,813                            7,629--53,17                                                                                                          Roche
  **TNFi**                                              Brennan et al. 2007 \[[@pone.0119683.ref015]\]       46,486 (TNFi as a group)                             \-                                        24,378--93,833                                                                                                        The British Society for Rheumatology (BSR)
  Kobelt et al. 2004 \[[@pone.0119683.ref016]\]         62,419                                               61,016                                               51,759--180,244                           Österlund and Kock Foundations, The King Gustav V 80 year fund and The Reumatikerförbundet                            
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       75,799 (TNFi+cDMARD)                                 57,092 (TNFi+cDMARD)                                 34,472--88,294 (TNFi+cDMARD)              Wyeth (now Pfizer)                                                                                                    
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       106,062 (TNFi)                                       88,146 (TNFi)                                        50 315--169 383 (TNFi)                    Wyeth (now Pfizer)                                                                                                    

➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, CADTH = Canadian Agency for Drugs and Technologies in Health, cDMARD = conventional disease-modifying antirheumatic drugs, CER = certolizumab pegol, ETN = etanercept, GOL = golimumab, GST = Gold, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, LEF = leflunomide, MTX = methotrexate, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year, SSZ = sulfasalazine, TNFi = TNF inhibitor, TOC = tocilizumab

Six studies performed comparisons between different biologics used in patients with an inadequate response to cDMARDs \[[@pone.0119683.ref020],[@pone.0119683.ref024],[@pone.0119683.ref028],[@pone.0119683.ref032],[@pone.0119683.ref033],[@pone.0119683.ref050]\]. The results of these studies were contradictory. Two studies \[[@pone.0119683.ref020],[@pone.0119683.ref024]\] found ETN to be dominant over IFX and ADA, while three of the other studies\[[@pone.0119683.ref028],[@pone.0119683.ref032],[@pone.0119683.ref050]\] reported ICERs ranging from 23,000 to 109,000 €/QALY for ETN when only direct costs were included ([Table 4](#pone.0119683.t004){ref-type="table"}). Two studies comparing TOC and ETN found TOC to be the dominant strategy. None of these CUAs included indirect costs.

10.1371/journal.pone.0119683.t004

###### Comparison of biologics in patients with an insufficient response to cDMARD.
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  Biologic   Comparator                                          Study                                                   ICER €/QALY (only direct costs)   Results of deterministic sensitivity analysis €/QALY   Source of research funding
  ---------- --------------------------------------------------- ------------------------------------------------------- --------------------------------- ------------------------------------------------------ ---------------------------------------------
  **IFX**    ETN                                                 Nguyen et al. 2012 \[[@pone.0119683.ref024]\]           ETN dominates                     \-                                                     One of the authors was funded by UCB Pharma
  CER        Nguyen et al. 2012 \[[@pone.0119683.ref024]\]       CER dominates                                           \-                                One of the authors was funded by UCB Pharma            
  **ADA**    GOL                                                 Nguyen et al. 2012 \[[@pone.0119683.ref024]\]           ADA dominates                     \-                                                     One of the authors was funded by UCB Pharma
  ETN        Nguyen et al. 2012 \[[@pone.0119683.ref024]\]       ETN dominates                                           \-                                One of the authors was funded by UCB Pharma            
  IFX        Chen et al. 2006 \[[@pone.0119683.ref028]\]         4,983---IFX is cost saving (ADA➔ cDMARDs)               \-                                NICE (UK)                                              
  IFX        Chen et al. 2006 \[[@pone.0119683.ref028]\]         ADA dominates (cDMARDs➔ ADA)                            \-                                NICE (UK)                                              
  **ETN**    IFX                                                 Barton et al. 2004 \[[@pone.0119683.ref050]\]           68,373                            42,760--88,266                                         NICE (UK)
  IFX        Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]   109,297 (ETN➔ cDMARDs)                                  51,908--231,484 (ETN➔ cDMARDs)    NICE (UK)                                              
  IFX        Jobanputra et al. 2002 \[[@pone.0119683.ref032]\]   101,714 (cDMARDs➔ETN)                                   30,597--180,270 (cDMARDs➔ ETN)    NICE (UK)                                              
  IFX        Chen et al. 2006 \[[@pone.0119683.ref028]\]         38,541--47,884 (ETN➔ cDMARDs)                           \-                                NICE (UK)                                              
  IFX        Chen et al. 2006 \[[@pone.0119683.ref028]\]         23,553 (cDMARDs➔ ETN)                                   \-                                NICE (UK)                                              
  ADA        Soini et al. 2012 \[[@pone.0119683.ref020]\]        ETN dominates                                           \-                                Roche                                                  
  ADA        Chen et al. 2006 \[[@pone.0119683.ref028]\]         35,621--61,315 (ETN➔ cDMARDs)                           \-                                NICE (UK)                                              
  ADA        Chen et al. 2006 \[[@pone.0119683.ref028]\]         22,579--30,755 (cDMARDs➔ ETN)                           \-                                NICE (UK)                                              
  **GOL**    ETN                                                 Nguyen et al. 2012 \[[@pone.0119683.ref024]\]           ETN dominates                     \-                                                     One of the authors was funded by UCB Pharma
  CER        Nguyen et al. 2012 \[[@pone.0119683.ref024]\]       CER dominates                                           \-                                One of the authors was funded by UCB Pharma            
  **CER**    ETN                                                 Nguyen et al. 2012 \[[@pone.0119683.ref024]\]           1 756,213                         \-                                                     One of the authors was funded by UCB Pharma
  **TOC**    ETN                                                 Diamantopoulos et al. 2012 \[[@pone.0119683.ref033]\]   TOC dominates                     TOC dominates---19,187                                 Roche
  ETN        Soini et al. 2012 \[[@pone.0119683.ref020]\]        TOC dominates---6,673                                   \-                                Roche                                                  

➔ = switch to next treatment in case of an inadequate response, ADA = adalimumab, CER = certolizumab pegol, ETN = etanercept, GOL = golimumab, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year, TOC = tocilizumab

Cost-effectiveness of biologics among patients with an inadequate response to at least one TNF inhibitor {#sec016}
--------------------------------------------------------------------------------------------------------

Eight CUAs compared biologics and cDMARDs in patients who had had an insufficient response to at least one TNFi \[[@pone.0119683.ref022],[@pone.0119683.ref025],[@pone.0119683.ref031],[@pone.0119683.ref034],[@pone.0119683.ref042],[@pone.0119683.ref043],[@pone.0119683.ref053],[@pone.0119683.ref054]\]. RTX was associated with the lowest ICERs ranging from 26,000 to 48,000 €/QALY ([Table 5](#pone.0119683.t005){ref-type="table"}). Three of four studies evaluating RTX provided ICERs below 35,000 €/QALY and none of the studies reported ICERs more than 50,000 €/QALY. ANA was associated with the highest ICERs with a range of 234,000--1 347,000 €/QALY. ICERs for the other agents ranged from 41,000 to 143,000 €/QALY. Inadequate comparator (MTX) was applied in three studies \[[@pone.0119683.ref034],[@pone.0119683.ref042],[@pone.0119683.ref043]\], and one study \[[@pone.0119683.ref025]\] did not specify the comparator cDMARDs. However, the ICERs of these studies did not differ from those of the other studies. Results of the four studies comparing one biologic to another \[[@pone.0119683.ref018],[@pone.0119683.ref031],[@pone.0119683.ref034],[@pone.0119683.ref053]\] indicated RTX as the most cost-effective biologic among patients with an insufficient response to a TNFi ([Table 6](#pone.0119683.t006){ref-type="table"}).

10.1371/journal.pone.0119683.t005

###### Cost-effectiveness of biologics in comparison with cDMARD among patients with an insufficient response to at least one TNF inhibitor.

![](pone.0119683.t005){#pone.0119683.t005g}

  Biologic                                              Study                                             ICER €/QALY (only direct costs)    ICER €/QALY (direct and indirect costs)   Results of deterministic sensitivity analysis €/QALY     Source of research funding
  ----------------------------------------------------- ------------------------------------------------- ---------------------------------- ----------------------------------------- -------------------------------------------------------- ----------------------------
  **RTX**                                               Yuan et al. 2010 \[[@pone.0119683.ref042]\]       47,931                             \-                                        57,370--96,012                                           BMS
  Kielhorn et al. 2008 \[[@pone.0119683.ref031]\]       28,594                                            \-                                 9,758--67,321                             Roche                                                    
  Brodszky et al. 2010 \[[@pone.0119683.ref034]\]       26,304--46,389                                    31,382--37,266                     \-                                        Center for Public Affairs Studies Foundation and Roche   
  Hallinen et al. 2010 \[[@pone.0119683.ref054]\]       34,269                                            \-                                 24,929--52,929                            Roche                                                    
  Malottki et al. 2011 \[[@pone.0119683.ref053]\]       30,021                                            \-                                 16,220--65,448                            NICE (UK)                                                
  **IFX**                                               Hallinen et al. 2010 \[[@pone.0119683.ref054]\]   40,923                             \-                                        36,174--48,483                                           Roche
  Malottki et al. 2011 \[[@pone.0119683.ref053]\]       51,362                                            \-                                 40,976--98,029                            NICE (UK)                                                
  **ADA**                                               Hallinen et al. 2010 \[[@pone.0119683.ref054]\]   57,713                             \-                                        48,963--68,930                                           Roche
  Malottki et al. 2011 \[[@pone.0119683.ref053]\]       48,801                                            \-                                 39,980--87,216                            NICE (UK)                                                
  **ETN**                                               Hallinen et al. 2010 \[[@pone.0119683.ref054]\]   57,068                             \-                                        48,294--68,285                                           Roche
  Malottki et al. 2011 \[[@pone.0119683.ref053]\]       55,346                                            \-                                 44,248--108,558                           NICE (UK)                                                
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       \-                                                74,743 (ETN+cDMARD)                47,164--113,453 (ETN+DMARD)               Wyeth (now Pfizer)                                       
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       \-                                                88,861 (ETN)                       53,769--175,126 (ETN)                     Wyeth (now Pfizer)                                       
  **ABT**                                               Hallinen et al. 2010 \[[@pone.0119683.ref054]\]   75,910                             \-                                        65,232--90,234                                           Roche
  Malottki et al. 2011 \[[@pone.0119683.ref053]\]       54,635                                            \-                                 45,671--90,062                            NICE (UK)                                                
  Vera-Llonch et al. 2008b \[[@pone.0119683.ref043]\]   45,275--49,802                                    \-                                 40,211--79,438                            Not stated, One of authors was an employee of BMS        
  Yuan et al. 2010 \[[@pone.0119683.ref042]\]           41,207                                            \-                                 49,912--81,509                            BMS                                                      
  **ANA**                                               Clark et al. 2004 \[[@pone.0119683.ref022]\]      620,109--1 347,287 (ANA➔cDMARDs)   \-                                        100,378--671,413                                         NICE (UK)
  Clark et al. 2004 \[[@pone.0119683.ref022]\]          234,214--292,210 (cDMARDs➔ANA)                    \-                                 82,533--216,370                           NICE (UK)                                                
  **TNFi**                                              Lekander et al. 2013 \[[@pone.0119683.ref025]\]   101,618 (TNFi+cDMARD)              84,363 (TNFi+cDMARD)                      50,316--134,016 (TNFi+cDMARD)                            Wyeth (now Pfizer)
  Lekander et al. 2013 \[[@pone.0119683.ref025]\]       143,745 (TNFi)                                    126,813 (TNFi)                     71,022--328,903 (TNFi)                    Wyeth (now Pfizer)                                       

➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, ANA = Anakinra, BMS = Bristol-Myers Squibb, cDMARD = conventional disease-modifying antirheumatic drugs, ETN = etanercept, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year, RTX = rituximab, TNFi = TNF inhibitor

10.1371/journal.pone.0119683.t006

###### Comparison of biologics among patients with an insufficient response to at least one TNF inhibitor.
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  Biologic              Comparator                                         Study                                             ICER €/QALY (only direct costs)   ICER €/QALY (direct and indirect costs)   Results of deterministic sensitivity analysis €/QALY   Source of research funding
  --------------------- -------------------------------------------------- ------------------------------------------------- --------------------------------- ----------------------------------------- ------------------------------------------------------ --------------------------------------------------------
  **RTX**               Another TNFi                                       Brodszky et al. 2010 \[[@pone.0119683.ref034]\]   RTX dominates                     RTX dominates                             \-                                                     Center for Public Affairs Studies Foundation and Roche
  2.TNFi➔ 3.TNFi        Lindgren et al. 2009 \[[@pone.0119683.ref045]\]    RTX dominant                                      RTX dominant                      RTX dominates---41,044                    Roche                                                  
  ADA ➔ IFX ➔ cDMARDs   Merkesdal et al. 2010 \[[@pone.0119683.ref018]\]   27,776                                            17,634                            8,050--54,441                             Roche                                                  
  ADA ➔ IFX ➔ cDMARDs   Kielhorn et al. 2008 \[[@pone.0119683.ref031]\]    22,581                                            \-                                \-                                        Roche                                                  
  **IFX**               RTX                                                Malottki et al. 2011 \[[@pone.0119683.ref053]\]   RTX dominates                     \-                                        5,833---RTX dominates                                  NICE (UK)
  **ADA**               RTX                                                Malottki et al. 2011 \[[@pone.0119683.ref053]\]   RTX dominates                     \-                                        612---RTX dominates                                    NICE (UK)
  ETN                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    ADA dominates                                     \-                                ADA dominates-103,578                     NICE (UK)                                              
  IFX                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    ADA dominates                                     \-                                27,033--40,834                            NICE (UK)                                              
  **ETN**               RTX                                                Malottki et al. 2011 \[[@pone.0119683.ref053]\]   RTX dominates                     \-                                        RTX dominates                                          NICE (UK)
  IFX                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    649,782                                           \-                                55,915---IFX dominates                    NICE (UK)                                              
  **ABT**               RTX                                                Malottki et al. 2011 \[[@pone.0119683.ref053]\]   185,815                           \-                                        73,273--1 225,153                                      NICE (UK)
  ADA                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    66,017                                            \-                                57,053--119,656                           NICE (UK)                                              
  ETN                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    53,781                                            \-                                47,663--71,992                            NICE (UK)                                              
  IFX                   Malottki et al. 2011 \[[@pone.0119683.ref053]\]    59,329                                            \-                                52,500--81,952                            NICE (UK)                                              

➔ = switch to next treatment in case of an inadequate response, ABT = abatacept, ADA = adalimumab, ETN = etanercept, ICER = Incremental cost-effectiveness ratio, IFX = infliximab, NICE = National Institute for Health and Care Excellence, QALY = quality-adjusted life year, RTX = rituximab, TNFi = TNF inhibitor

Other studies {#sec017}
-------------

Three studies did not specify patients' previous treatments, and therefore were not included in the subgroups described above \[[@pone.0119683.ref037],[@pone.0119683.ref040],[@pone.0119683.ref047]\]. Farahani *et al*. estimated ICER for ETN in comparison to cDMARDs to be 71,000 €/QALY while applying the efficacy estimates based on a RCT and 150,000 €/QALY when effectiveness estimates from an observational study were used \[[@pone.0119683.ref037]\]. Chiou *et al*. and Wailoo *et al*. performed comparisons of different biologics \[[@pone.0119683.ref040],[@pone.0119683.ref047]\]. Both studies reported ETN to be dominant over IFX. Chiou *et al*. also found ETN to dominate ADA while Wailoo *et al*. estimated ICER of 95,000 €/QALY for ETN in comparison to ADA.

Quality of the included studies {#sec018}
-------------------------------

The average quality scores of the 41 studies included in the present review were 25.7 out of 35 (range 17 to 31) and 32.3 out of 57 (range 16 to 46) when evaluated using BMJ checklist and Philips' list, respectively ([Table 7](#pone.0119683.t007){ref-type="table"}). The corresponding average percentages of the applicable items fulfilled were 81 (range 57 to 100) and 62 (range 31 to 90) for BMJ check list and Philips' list, respectively. The most frequent quality issues were the incomplete reporting of the data sources, inappropriate comparator treatments, defects in the sensitivity analysis and the lack of quality assessment of data used.

10.1371/journal.pone.0119683.t007

###### Results of quality assessment.
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  Study                                                                  BMJ quality scores, max = 35 (items applicable in each study)   Applicable items %   Philip's quality scores, max = 57 (items applicable in each study)   Applicable items %   Quality category
  ---------------------------------------------------------------------- --------------------------------------------------------------- -------------------- -------------------------------------------------------------------- -------------------- ------------------
  Bansback et al. 2005, Sweden \[[@pone.0119683.ref041]\]                23 (31)                                                         74                   38 (52)                                                              73                   Adequate
  Barbieri et al. 2005, UK \[[@pone.0119683.ref051]\]                    25 (31)                                                         81                   23 (53)                                                              43                   Poor
  Barton et al. 2004, UK \[[@pone.0119683.ref050]\]                      29 (31)                                                         94                   40 (49)                                                              82                   Good
  Brennan et al. 2004, UK \[[@pone.0119683.ref049]\]                     29 (33)                                                         88                   30 (54)                                                              56                   Adequate
  Brennan et al. 2007, UK \[[@pone.0119683.ref015]\]                     26 (32)                                                         81                   37 (49)                                                              76                   Good
  Brodszky et al. 2010, Hungary \[[@pone.0119683.ref034]\]               19 (30)                                                         63                   16 (52)                                                              31                   Poor
  CADTH 2010, Canada \[[@pone.0119683.ref048]\]                          17 (30)                                                         57                   18 (53)                                                              34                   Poor
  Chen et al. 2006, UK \[[@pone.0119683.ref028]\]                        31 (31)                                                         100                  46 (51)                                                              90                   Good
  Chiou et al. 2004, \[[@pone.0119683.ref047]\]                          23 (31)                                                         74                   20 (53)                                                              38                   Poor
  Clark et al. 2004, UK \[[@pone.0119683.ref022]\]                       30 (31)                                                         97                   40 (50)                                                              80                   Good
  Coyle et al. 2006, Canada \[[@pone.0119683.ref046]\]                   29 (31)                                                         94                   28 (52)                                                              54                   Adequate
  Davies et al. 2009 USA \[[@pone.0119683.ref021]\]                      29 (32)                                                         91                   38 (55)                                                              69                   Good
  Diamantopoulos et al. 2012, Italy \[[@pone.0119683.ref033]\]           25 (32)                                                         78                   32 (55)                                                              58                   Adequate
  Farahani et al. 2006, Canada \[[@pone.0119683.ref037]\]                19 (27)                                                         70                   No modelling used                                                    \-                   Poor
  Finckh et al. 2009, USA \[[@pone.0119683.ref027]\]                     28 (32)                                                         88                   36 (54)                                                              67                   Good
  Hallinen et al. 2010, Finland \[[@pone.0119683.ref054]\]               29 (31)                                                         94                   28 (52)                                                              54                   Adequate
  Jobanputra et al. 2002, UK \[[@pone.0119683.ref032]\]                  28 (31)                                                         90                   34 (49)                                                              69                   Good
  Kielhorn et al. 2008, UK \[[@pone.0119683.ref031]\]                    25 (31)                                                         81                   37 (53)                                                              70                   Adequate
  Kobelt et al. 2003, UK & Sweden \[[@pone.0119683.ref052]\]             23 (32)                                                         72                   22 (49)                                                              45                   Poor
  Kobelt et al. 2004, Sweden \[[@pone.0119683.ref016]\]                  25 (30)                                                         83                   No modelling used                                                    \-                   Adequate
  Kobelt et al. 2005, Sweden \[[@pone.0119683.ref036]\]                  22 (33)                                                         67                   28 (53)                                                              53                   Poor
  Kobelt et al. 2011, Sweden \[[@pone.0119683.ref038]\]                  26 (33)                                                         79                   28 (54)                                                              52                   Poor
  Lekander et al. 2010, Sweden \[[@pone.0119683.ref026]\]                23 (33)                                                         70                   31 (51)                                                              61                   Poor
  Lekander et al. 2013, Sweden \[[@pone.0119683.ref025]\]                24 (33)                                                         73                   37 (53)                                                              70                   Adequate
  Lindgren et al. 2009, Sweden \[[@pone.0119683.ref045]\]                22 (33)                                                         67                   34 (48)                                                              71                   Adequate
  Malottki et al. 2011, UK \[[@pone.0119683.ref053]\]                    29 (31)                                                         94                   46 (52)                                                              88                   Good
  Marra et al. 2007, Canada \[[@pone.0119683.ref044]\]                   27 (33)                                                         82                   31 (54)                                                              57                   Adequate
  Merkesdal et al. 2010, Germany \[[@pone.0119683.ref018]\]              27 (32)                                                         84                   34 (52)                                                              65                   Adequate
  Nguyen et al. 2012, USA \[[@pone.0119683.ref024]\]                     25 (31)                                                         81                   28 (55)                                                              51                   Poor
  Schipper et al. 2011, the Netherlands \[[@pone.0119683.ref030]\]       25 (33)                                                         76                   34 (52)                                                              65                   Adequate
  Soini et al. 2012, Finland \[[@pone.0119683.ref020]\]                  31 (33)                                                         94                   42 (54)                                                              78                   Good
  Spalding & Hay 2006, USA \[[@pone.0119683.ref014]\]                    23 (32)                                                         72                   30 (52)                                                              58                   Poor
  Tanno et al. 2006, Japan \[[@pone.0119683.ref035]\]                    29 (32)                                                         91                   23 (51)                                                              45                   Adequate
  Wailoo et al. 2008, USA \[[@pone.0119683.ref040]\]                     25 (31)                                                         81                   36 (55)                                                              65                   Adequate
  van den Hout et al. 2009, the Netherlands \[[@pone.0119683.ref019]\]   29 (31)                                                         94                   No modelling used                                                    \-                   Good
  Welsing et al. 2004, the Netherlands \[[@pone.0119683.ref023]\]        22 (32)                                                         69                   27 (55)                                                              49                   Poor
  Vera-Llonch et al. 2008a, USA \[[@pone.0119683.ref017]\]               26 (32)                                                         81                   37 (50)                                                              74                   Good
  Vera-Llonch et al. 2008b, USA \[[@pone.0119683.ref043]\]               27 (32)                                                         84                   37 (50)                                                              74                   Good
  Wong et al. 2002 \[[@pone.0119683.ref039]\]                            23 (33)                                                         70                   24 (51)                                                              47                   Poor
  Wu et al. 2012, China \[[@pone.0119683.ref029]\]                       30 (32)                                                         94                   41 (54)                                                              76                   Good
  Yuan et al. 2010, USA \[[@pone.0119683.ref042]\]                       23(32)                                                          72                   36 (53)                                                              68                   Adequate

Discussion {#sec019}
==========

We performed a systematic literature review of cost-effectiveness of biologics used for the treatment of RA. After the literature search and the selection process of the initially identified reports, 41 original articles were included in the current review. While considering only direct costs, the ICERs of the TNFis ranged from 39,000 to 1 273,000 €/ QALY in comparison to cDMARD in patients naïve to cDMARDs. Among patients with an inadequate response to cDMARDs, biologics were associated with ICERs ranging from 12,000 to 708,000 €/QALY. In this setting, none of the biologics appeared to be more cost-effective than any of the others. ICERs for the second line biologics ranged from 26,000 to 1 347,000 €/QALY in comparison to cDMARDs among patients with an inadequate response to TNFi. In this patient subgroup RTX was the most and ANA the least cost-effective biologic. The quality assessment revealed several problems, namely insufficient reporting of data sources and problematic methodological details, which possibly reduce the validity of the results.

When assessing whether biologics are cost-effective or not, it should be known what the willingness to pay for an additional QALY is. There is no widely accepted WTP threshold value for ICER although the National Institute for Health and Care Excellence (NICE) has published a threshold of 20,000--30,000 £/QALY (\~24,000--35,000 €/QALY) in United Kingdom \[[@pone.0119683.ref055]\]. Based on this statement by NICE we used the WTP threshold of 35,000 €/QALY. With this threshold biologics are not cost-effective in cDMARD naïve patients. However, also much higher WTP thresholds have been proposed and applied in the literature, but even with the 100,000 €/QALY threshold biologics do not seem to be cost-effective in this patient subgroup. Slightly more preferable ICERs for ADA and ETN monotherapies do not count either: TNFi monotherapy has later been found less effective than its combination with MTX and therefore, biologics as monotherapies are not currently recommended \[[@pone.0119683.ref003],[@pone.0119683.ref005]\]. In patients who have an insufficient response to cDMARDs, biologics are not cost-effective with the 35,000 €/QALY threshold, and with the higher thresholds of 50,000--100,000 €/QALY the evidence of their cost-effective is conflicting. It should be noted that ADA, ETN and IFX, which have been for the longest time on the market, have been assessed in several studies and are consequently associated with a wide range of different ICERs. Meanwhile the narrower ranges of ICER values for ABT and TOC probably reflect the lower number of studies rather than more consistent performance of these agents. Health technology assessment reports provided by independent organisations such as NICE tend to provide higher ICERs than CUAs funded by pharmaceutical companies, due to different premises of the studies. Such publicly funded and in this respect independent reports are not yet available for the newer agents such as TOC, which also may at least in part explain more favourable ICERs. Among the patients with an inadequate response to one TNFi, RTX appears cost-effective with the threshold of 35,000 €/QALY. With the higher thresholds also other TNFis and ABT might be cost effective. These findings are consistent with previous systematic reviews on the current topic \[[@pone.0119683.ref008]--[@pone.0119683.ref010]\].

We performed this review following current recommendations for systematic literature review of economic evaluations \[[@pone.0119683.ref011]\]. Standardized methodology is a certain guarantee for the quality and reliability of the current work. Source studies were restricted to CUAs, instead of all CEAs, because QALY as a single measure of the effectiveness enables more accurate comparison of the results. A further aim was to enhance the comparability of the studies by classifying them by previous treatments and comparator treatments. Such a classification seems almost to be necessary because the patient history is a key factor while assessing the external validity and trying to generalize the results and because the comparator treatment has a great impact on ICERs.

The importance of adequate comparator has been previously raised by Tsao and colleagues in their systematic review examining the cost-effectiveness of biologics in comparison to cDMARDs \[[@pone.0119683.ref009]\]. MTX was the most frequent comparator in the studies included in the current systematic review. MTX is the drug of choice in cDMARD naïve patient population \[[@pone.0119683.ref003]\]. On the other hand, in patients with MTX monotherapy treatment failure this drug does not represent an adequate treatment option. Instead patients should be treated with other cDMARDs or a combination of cDMARDs they have not received before. In the current study ICERs were assessed using comparator treatments and it seems that CUAs applying adequate comparators may provide rather high ICERs. However, in spite of the general acceptance of MTX as an anchor drug in RA, there is a lack of consensus on the optimal cDMARDs sequence, which poses a problem for CUAs.

It should be noticed that in spite of stratification of patients to subgroups, methodological differences make a comparison of different CUAs difficult. Heterogeneity in time horizons, discount rates, and perspectives were observed, all possibly inducing differences between the studies. For example, it is likely that a CUA with a longer time horizon produces more favourable ICERs compared to ones with shorter time horizons \[[@pone.0119683.ref017],[@pone.0119683.ref036],[@pone.0119683.ref043]\]. While biologics are expensive, they might induce future savings through decreased productivity losses and the lesser need for surgery and inpatient care. A discount rate depreciates the future costs and benefits of the treatment consequently reducing their impact on ICER.

Analyses counting only direct costs give an incomplete view of the pros and cons of different treatments, while various methods used to estimate indirect costs remain controversial. In the current study ICERs based only on direct costs and ICERs based on the inclusion of both direct and indirect costs are provided if they were reported in the original source publication. It is likely that biologics decrease productivity costs because they improve the health status of the patients \[[@pone.0119683.ref005],[@pone.0119683.ref006]\]. However, the age and employment status of treated population and the overall labour costs have a major impact on indirect costs, introducing heterogeneity in the ICERs. For example, in China where labour costs are low, Wu *et al*. reported only small differences between ICERs including direct or both direct and indirect costs, while in Sweden much larger differences were observed \[[@pone.0119683.ref025],[@pone.0119683.ref029],[@pone.0119683.ref036],[@pone.0119683.ref038],[@pone.0119683.ref052]\]. The method used for the evaluation of productivity costs generate further variation in ICERs when also indirect costs are considered: Van den Hout *et al*. reported ICERs of 147,000€/QALY and 25,000€/QALY for early IFX treatment using friction cost and human capital methods, respectively \[[@pone.0119683.ref019]\]. For these reasons it is more transparent not to use ICERs with indirect costs when results of different studies are to be compared. Accordingly, conclusions in the current review are based on ICERs including only direct costs. Health service and other costs are always also related to national economy, health policy and price level and thus ICERs cannot directly be generalized when analysing results from different countries.

Different methodologies used for the QALY measures have effect on ICERs. In most studies, the utility scores of the multiattribute utility (MAU) instruments (e.g. EQ-5D) were derived from the Health assessment questionnaire (HAQ) or some other disease specific measures. This is necessary due to the fact that the MAU instruments have been applied in few RCTs, while disease specific measures such as HAQ have been commonly used in RCTs. Application of different formulas for conversions introduce a further source of heterogeneity in ICERs estimates \[[@pone.0119683.ref044]\]. Different MAU instruments without any conversions produce different utility scores and hence, different ICERs \[[@pone.0119683.ref019]\]. Standardization of MAU instruments and a validated standard conversion method for missing utility measures would enable better comparison between different CUAs.

In most studies the effectiveness estimates were based on one or several RCTs, representing rather estimates for efficacy. While RCTs are the key source for the efficacy evidence in medicines, they have some weaknesses if applied as source of effectiveness estimates in economic evaluations. Firstly, the results of RCTs are generally better than in the clinical practice because patients are carefully selected and adherence is usually better to RCTs than to regular clinical practices. Consequently, ICERs based on efficacy estimates from RCTs tend to be much lower than those based on observational data as shown by Farahani *et al*. \[[@pone.0119683.ref037]\]. Secondly, an objective of RCTs is usually to explore an efficacy of a single treatment in comparisons to placebo (or MTX in case of several RCTs studying biologics for RA), rather than compare complex treatment strategies. In contrast, CUAs aim to compare active treatments reflecting real life practices, and therefore indirect comparisons of RCTs are often necessary. However, some CUAs which used effectiveness estimates obtained from several RCTs reported indirect comparisons inadequately. This, restricted clinical evidence and therefore somewhat inconsistent results from CUAs explain that the ranking of biologics remains unclear among patients having inadequate response for cDMARDs \[[@pone.0119683.ref006]\]. To advance CUAs even further, indirect comparisons could in the future be performed and reported according to current guidelines \[[@pone.0119683.ref056]\].

The quality of economic evaluations was assessed using two different checklists, and was found to be suboptimal. The quality scores according the BMJ checklist were rather high while Philips' checklist provided less favorable estimates of the study qualities. The reason for this discrepancy is probably the extensiveness of the Philips' checklist, which covers several topics not considered in the BMJ checklist. An interesting finding was that quality scores of the studies were not associated with the magnitude of ICER. This is perhaps based on the nature of checklists: a single and simple modeling assumption may have a great impact on ICERs even if its effect on quality scores remains minor. In addition to the quality assessment of the individual studies, we assessed the bias across the CUAs. Only a few of the older conference abstracts identified through the literature search have been published later as a full article, indicating a reporting bias. However, conference abstracts were not included in the current systematic literature review due to incomplete information and problems with quality assessment that may bias their results. The risk of a language bias seems minor based on the small number of non-English papers excluded.

Conclusions {#sec020}
===========

With the WTP threshold of 35,000 €/QALY, biologics do not seem to be cost-effective among cDMARD naïve patients or cDMARD resistant patients. Among patients with an inadequate response to TNFi(s), RTX seems to be cost-effective. With thresholds of 50,000--100,000 €/QALY biologics might be cost-effective among cDMARD resistant patients.
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